Maarten Cozijnsen

124 Table 2. Overview of studies that compared the efficacy of combination therapy to anti-TNF monotherapy in pediatric and adult UC patients Type Year Authors Patients N Treatment Duration Post-hoc analyses of RCT* 2012 Hyams et al (T72)(7) Pediatric UC, moderate-to-severe disease 60 [1] IFX+IM; [2] IFX 54 wks Observational 2010 Hyams et al (39) Pediatric UC 52 [1] IFX+IM; [2] IFX 104 wks RCT 2014 Panaccione et al (UC- SUCCESS)(12) Adult UC, moderate- to-severe disease 239 [1] IFX+AZA; [2] IFX+PCB [3] AZA+PCB 16 wks Post-hoc analysis of 4 IFX RCTs* 2009 Lichtenstein et al (25) Adult UC, moderate- to-severe disease 1383 [1] IFX+IM; [2] IFX* 30-54 wks Observational 2013 Armuzzi et al (40) Adult UC, active disease 126 [1] IFX+IM; [1a] TP naïve [1b] TP exp [2] IFX* 52 wks Retrospective 2014 Hayes et al Adult UC 85 [1] IFX+IM [2] IFX Observational 2013 Jeuring et al (42) Adult UC 109 [1] IFX+IM [2] IFX N=number; RCT=randomized clinical trial; UC=ulcerative colitis; IFX=infliximab; IM=immunomodulator (AZA or 6-mercaptopurine or MTX); AZA=azathioprine; MTX=methotrexate; TP=thiopurine; exp=experienced; wk=week; CFCR=Corticosteroid-free clinical remission; ATIs=antibodies-to- infliximab; MH=mucosal healing; HR=hazard ratio. * Treatment of the two groups of the sub analysis, not of the randomization arms. ** When the P-value is followed by the “≈” symbol, no P-value is provided in the original article; we estimated the P-value using Fisher Exact Test